Stocks
Apteki 36.6 Financial Statements (APTK) |
|||||||
| Аптеки 36 и 6smart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Report date | 30.04.2020 | 30.04.2021 | 08.08.2023 | 17.07.2023 | 02.05.2024 | ||
| Currency | RUB | RUB | RUB | RUB | RUB | ||
| Financial report URL | |||||||
| Annual report URL | |||||||
| Revenue, bln rub | ? | 46.1 | 39.3 | 44.1 | 59.1 | 67.4 | |
| EBITDA, bln rub | ? | -3.59 | 4.70 | ||||
| Net profit, bln rub | ? | -8.86 | 6.40 | -0.950 | 0.223 | 0.120 | |
| OCF, bln rub | ? | 3.23 | 6.60 | 7.05 | |||
| CAPEX, bln rub | ? | 1.82 | 1.70 | 0.980 | 0.980 | 0.650 | |
| FCF, bln rub | ? | -1.71 | 1.64 | 2.68 | |||
| Ordinary share dividend yield, % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
| Dividend payout ratio, % | 0% | 0% | 0% | 0% | 0% | ||
| Cost of production, bln rub | 32.9 | 25.7 | 29.0 | 38.9 | 45.1 | ||
| Amortization, bln rub | 5.8 | 5.8 | 6.0 | ||||
| Employment expenses, bln rub | 6.31 | 6.27 | 6.78 | 7.92 | 8.91 | ||
| Interest expenses, bln rub | 4.30 | 4.05 | 4.92 | 4.27 | 4.06 | ||
| Assets, bln rub | 32.6 | 54.4 | 37.8 | 43.6 | 53.2 | ||
| Net Assets, bln rub | ? | -23.6 | -5.70 | -6.65 | -6.41 | -6.83 | |
| Debt, bln rub | 33.2 | 40.2 | 21.6 | 18.9 | 20.7 | ||
| Cash, bln rub | 0.850 | 1.000 | 1.73 | 0.810 | 2.09 | ||
| Net debt, bln rub | 32.3 | 39.2 | 19.9 | 18.1 | 18.6 | ||
| Ordinary share price, rub | 12.3 | 14.0 | 14.0 | 11.6 | 14.2 | ||
| Number of ordinary shares, mln | 2 331 | 2 331 | 2 331 | 2 331 | 2 331 | ||
| Market cap, bln rub | 28.6 | 32.5 | 32.5 | 27.0 | 33.1 | ||
| EV, bln rub | ? | 60.9 | 71.7 | 52.4 | 45.1 | 51.7 | |
| Book value, bln rub | -33.2 | -18.2 | -19.5 | -19.9 | -24.0 | ||
| EPS, rub | ? | -3.80 | 2.75 | -0.41 | 0.10 | 0.05 | |
| FCF/share, rub | 0.00 | 0.00 | -0.73 | 0.70 | 1.15 | ||
| BV/share, rub | -14.2 | -7.81 | -8.37 | -8.54 | -10.3 | ||
| EBITDA margin, % | ? | -7.8% | 12.0% | 0.0% | 0.0% | 0.0% | |
| Net margin, % | ? | -19.2% | 16.3% | -2.2% | 0.4% | 0.2% | |
| FCF yield, % | ? | 0.0% | 0.0% | -5.3% | 6.1% | 8.1% | |
| ROE, % | ? | 37.6% | -112.3% | 14.3% | -3.5% | -1.8% | |
| ROA, % | ? | -27.2% | 11.8% | -2.5% | 0.5% | 0.2% | |
| P/E | ? | -3.23 | 5.08 | -34.2 | 120.9 | 276.2 | |
| P/FCF | -19.0 | 16.4 | 12.4 | ||||
| P/S | ? | 0.62 | 0.83 | 0.74 | 0.46 | 0.49 | |
| P/BV | ? | -0.86 | -1.79 | -1.67 | -1.35 | -1.38 | |
| EV/EBITDA | ? | -17.0 | 15.2 | ||||
| Debt/EBITDA | -9.00 | 8.33 | |||||
| Employees, people | 5 904 | ||||||
| Labour productivity, mln rub/person/year | 6.66 | ||||||
| Expenses per employee, thousand rub | 1 062 | ||||||
| R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| CAPEX/Revenue, % | 4% | 4% | 2% | 2% | 1% | ||
| Apteki 36.6 shareholders | |||||||
